Notice: Trying to access array offset on value of type bool in /home/oculusis/public_html/intradermeu.com/wp-content/plugins/ubermenu/standard/UberMenuStandard.class.php on line 270
next-generation hydrogel and solution combo pack that provides an anti-inflammatory and antimicrobial effect to treat mild-to-moderate acne
GramaDerm next-generation hydrogel and solution combo pack that provides an anti-inflammatory and antimicrobial effect to treat mild-to-moderate acne 2018-09-04T15:55:51+00:00

Deprecated: wp_make_content_images_responsive is deprecated since version 5.5.0! Use wp_filter_content_tags() instead. in /home/oculusis/public_html/intradermeu.com/wp-includes/functions.php on line 4859
GramaDerm Combo-pack for Acne

GramaDerm™ is a next-generation hydrogel and solution combo pack that provides an anti-inflammatory and antimicrobial effect to treat mild-to-moderate acne.

  • Safe to use around mouth, eyes and nose
  • Non-toxic, non-irritating and non-staining
  • Supports the body’s own healing process
  • Both anti-inflammatory and antimicrobial

In a 12-week double-blinded, placebo-controlled, parallel-group, randomized clinical trial with GramaDerm™ vs benzoyl peroxide among 87 patients, the outcome was significant compared to the standard acne treatment with benzoyl peroxide.

Number of lesions

Number of Lessions

  • In this pilot study, application of GramaDerm™ reduced prevalence of acne blemishes by 65% versus 54% for benzoyl peroxide .
  • GramaDerm™ eliminated 98% of propionibacterium acnes in 60 seconds without inducing bacteria resistance.
  • No adverse effects were associated with the use of GramaDerm™ while benzoyl peroxide was associated with stinging, bacterial resistance, erythema and drying or peeling of the skin.

GramaDerm Results

The effect of GramaDerm™ on mild-to-moderate inflammatory acne lesions at baseline (A) and at 12 weeks (B).

Download Brochure (PDF)

Journal of Dermatological Treatment. 2009; 20:289–292 Efficacy and tolerance of super oxidized solution in the treatment of mild to moderate inflammatory acne. A double-blinded, placebo-controlled, parallel-group, randomized, clinical trial. Andrés Tirado-Sánches & Rosa Maria Ponce-Olivera. Full study details upon request by calling +31 (0)475 318666